CA
ARQT icon

Clearstead Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Clearstead Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$185 Buy
+7
New +$163 ﹤0.01% 3223
2026
Q1 		– Sell
-20
Closed -$581 – 2286
2025
Q4 		$581 Sell
20
-176
-90% -$4.51K ﹤0.01% 2295
2025
Q3 		$3.69K Buy
196
+59
+43% +$930 ﹤0.01% 2270
2025
Q2 		$1.92K Buy
+137
New +$1.92K ﹤0.01% 2336

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Clearstead Advisors's ARQT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 7 shares worth $185. The stake represents ﹤0.01% of the portfolio and ranks #3223 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ARQT as recently as Q4 2025.

Clearstead Advisors first reported a position in ARQT in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.69K in Q3 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Clearstead Advisors held 7 shares of Arcutis Biotherapeutics worth $185 as of Q2 2026.
  • Arcutis Biotherapeutics was a new Clearstead Advisors position in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3223 holding.
  • Clearstead Advisors first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 4 quarters since.
  • Clearstead Advisors's Arcutis Biotherapeutics position peaked at $3.69K in Q3 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.